A phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 3, 2012, Pages 255-260

  You, Benoit ^a   Le Tourneau, Christophe ^a   Chen, Eric X ^a   Wang, Lisa ^b   Jarvi, Andrea ^a   Bharadwaj, Rikki R ^b   Kamel Reid, Suzanne ^b   Perez Ordonez, Bayardo ^c   Mann, Vijay ^d   Siu, Lillian L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Department of Medical Affairs   (Canada)

Author keywords

Epstein Barr virus; erlotinib; gemcitabine; nasopharyngeal neoplasms; platinum compounds

Indexed keywords

CARBOPLATIN; CISPLATIN; ERLOTINIB; GEMCITABINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CREATININE CLEARANCE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; EPSTEIN BARR VIRUS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEARING LOSS; HUMAN; HYPOKALEMIA; HYPONATREMIA; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; QUANTITATIVE ANALYSIS; RASH; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84861527826     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31820dbdcc     Document Type: Article

References (30)

1. O'SulliVan B. Nasopharynx cancer: therapeutic value of chemoradiotherapy Int J Radiat Oncol Biol Phys. 2007;69(2 suppl): S118-S121
2. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally adVanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients Int J Radiat Oncol Biol Phys. 2006;64:47-56
3. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with adVanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317
4. Chan AT, Felip E. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(suppl 4):123-125
5. Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008;99:1311-1318
6. Jiang Y, Wei YQ, Luo F, et al. Gemcitabine and cisplatin in adVanced nasopharyngeal carcinoma: a pilot study. Cancer Invest 2005;23:123-128
7. Ma BB, Tannock IF, Pond GR, et al. Chemotherapy with gemcitabine- containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer. 2002;95:2516-2523
8. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13: 1252-1258
9. Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 2003;25:864-872
10. Miller WE, Cheshire JL, Baldwin AS Jr, et al. The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells. Oncogene. 1998;16: 1869-1877
11. Yip KW, Shi W, Pintilie M, et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res. 2006;12:5726-5732
12. Ma B, Hui EP, King A, et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol. 2008;62:59-64
13. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with adVanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461-2470
14. To EW, Chan KC, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res. 2003;9:3254-3259
15. Hsu CH, Gao M, Chen CL, et al. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology. 2005;68:538-547
16. Sung FL, Poon TC, Hui EP, et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. In Vivo. 2005;19:237-245
17. Zhu XF, Liu ZC, Xie BF, et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 2001;169:27-32
18. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with adVanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132
20. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in adVanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552
21. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in adVanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-5899
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216
23. Makitie AA, Reis PP, Irish J, et al. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally adVanced nasopharyngeal cancer: a pilot study Head Neck. 2004;26:815-822
24. Chua DT, Wei WI, Wong MP, et al. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma Head Neck. 2008;30:863-867
25. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967
26. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350: 2129-2139
27. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
28. Shepherd FA, Tsao MS. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. J Clin Oncol. 2010; 28:903-905
29. Lee SC, Lim SG, Soo R, et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics. 2006;16:73-74
30. Chan ATC, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-3576